U.S. Markets open in 8 hrs 17 mins
  • S&P Futures

    3,723.50
    +33.25 (+0.90%)
     
  • Dow Futures

    29,766.00
    +228.00 (+0.77%)
     
  • Nasdaq Futures

    11,410.00
    +124.25 (+1.10%)
     
  • Russell 2000 Futures

    1,734.70
    +19.80 (+1.15%)
     
  • Crude Oil

    83.85
    +0.22 (+0.26%)
     
  • Gold

    1,708.60
    +6.60 (+0.39%)
     
  • Silver

    20.91
    +0.32 (+1.53%)
     
  • EUR/USD

    0.9842
    +0.0015 (+0.1476%)
     
  • 10-Yr Bond

    3.6510
    0.0000 (0.00%)
     
  • Vix

    30.10
    -1.52 (-4.81%)
     
  • GBP/USD

    1.1334
    +0.0015 (+0.1303%)
     
  • USD/JPY

    144.7670
    +0.1470 (+0.1016%)
     
  • BTC-USD

    19,600.25
    +503.52 (+2.64%)
     
  • CMC Crypto 200

    446.05
    +10.70 (+2.46%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,981.34
    +765.55 (+2.92%)
     

Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference

·2 min read

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on Monday, January 10, 2022 at 7:30 a.m. PT/ 10:30 a.m. ET. The virtual conference will be held from January 10-13, 2022.

A direct link to the presentations can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for a limited time following the event. To access the link, please visit Halozyme's website approximately 10 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed using ENHANZE®. Halozyme is headquartered in San Diego. For more information visit Halozyme.com and connect with us on LinkedIn and Twitter.

Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-virtually-at-the-40th-annual-jp-morgan-health-care-conference-301453276.html

SOURCE Halozyme Therapeutics, Inc.